Jean-Emmanuel Sarry

List of Publications by Year
in descending order

87	4,834	117625	98798
papers	citations	34 h-index	67 g-index

98	98	98	8142
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Reports, 2022, 38, 110197.	6.4	22
2	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	7.2	12
3	Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions. Cell Death and Disease, 2022, 13, 448.	6.3	22
4	Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3â€ITDâ€driven acute myeloid leukemia. FEBS Open Bio, 2021, 11, 48-60.	2.3	4
5	Reference Values for Hematology, Plasma Biochemistry, Bone Marrow Cytology and Bone Histology of NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/ SzJ Immunodeficient Mice. Journal of the American Association for Laboratory Animal Science, 2021, 60, 4-17.	1.2	6
6	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. Journal of Experimental Medicine, 2021, 218, .	8.5	56
7	Disrupting Mitochondrial Electron Transfer Chain Complex I Decreases Immune Checkpoints in Murine and Human Acute Myeloid Leukemic Cells. Cancers, 2021, 13, 3499.	3.7	10
8	Autophagy is a major metabolic regulator involved in cancer therapy resistance. Cell Reports, 2021, 36, 109528.	6.4	55
9	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. Nature Communications, 2021, 12, 422.	12.8	36
10	Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy. Leukemia, 2021, 35, 417-432.	7.2	22
11	Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations. Cancers, 2021, 13, 5243.	3.7	6
12	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1204-1223.	13.2	42
13	SHED-Dependent Oncogenic Signaling of the PEAK3 Pseudo-Kinase. Cancers, 2021, 13, 6344.	3.7	6
14	Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients. Cancers, 2021, 13, 6353.	3.7	3
15	Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. Cancers, 2020, 12, 2933.	3.7	7
16	Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. Nature Communications, 2020, 11, 4056.	12.8	96
17	Microenvironmental Aspartate Preserves Leukemic Cells from Therapy-Induced Metabolic Collapse. Cell Metabolism, 2020, 32, 321-323.	16.2	3
18	Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation. Haematologica, 2020, 105, 987-9998.	3.5	18

#	Article	IF	Citations
19	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 2020, 12, 1725.	3.7	13
20	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. Cancer Discovery, 2020, 10, 1544-1565.	9.4	39
21	Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia. Haematologica, 2020, 105, e280-e284.	3.5	2
22	Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. Cancer Research, 2019, 79, 5191-5203.	0.9	45
23	Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. Oncogenesis, 2019, 8, 39.	4.9	26
24	Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. BMC Biology, 2019, 17, 57.	3.8	31
25	Help from outside: cysteine to survive in AML. Blood, 2019, 134, 336-338.	1.4	5
26	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 131-142.	2.2	57
27	Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models. Blood, 2019, 134, 2671-2671.	1.4	0
28	Targeting the SUMO Pathway Primes All-trans Retinoic Acidâ€“Induced Differentiation of Nonpromyelocytic Acute Myeloid Leukemias. Cancer Research, 2018, 78, 2601-2613.	0.9	45
29	Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica, 2018, 103, 988-998.	3.5	49
30	Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene, 2018, 37, 787-797.	5.9	82
31	RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. Leukemia, 2018, 32, 597-605.	7.2	22
32	Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2018, 19, 3325.	4.1	46
33	Adrenomedullin Receptor Calcrl Drives Drug Resistance of Leukemic Stem Cells in Acute Myeloid Leukemia. Blood, 2018, 132, 1449-1449.	1.4	1
34	Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia. Blood, 2018, 132, 5238-5238.	1.4	2
35	Extracellular ATP and CD39 Regulates Mitochondrial Function and Cytarabine Resistance through Intrinsic PKA-ATF-PGC1a Pathway in Acute Myeloid Leukemia. Blood, 2018, 132, 2737-2737.	1.4	2
36	Assessment of tumor-infiltrating TCRVÎ³9VÎ´2Î³Î´lymphocyte abundance by deconvolution of human cancers microarrays. OncoImmunology, 2017, 6, e1284723.	4.6	134

#	Article	IF	Citations
37	High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia, 2017, 31, 2326-2335.	7.2	106
38	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.	9.4	582
39	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
40	Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment. Cell Metabolism, 2017, 26, 705-707.	16.2	140
41	Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia. Leukemia, 2017, 31, 755-759.	7.2	20
42	Toward the Analysis of Mitochondria Isolated from Leukemic Cells with Electrochemically Instrumented Microwell Arrays. Proceedings (mdpi), 2017, 1, .	0.2	2
43	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood, 2016, 127, 882-892.	1.4	108
44	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood, 2016, 128, 253-264.	1.4	320
45	CHK1 as a therapeutic target to bypass chemoresistance in AML. Science Signaling, 2016, 9, ra90.	3.6	73
46	Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53. Molecular Cell, 2016, 62, 890-902.	9.7	96
47	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.	8.5	68
48	Abstract 5203: Innovative and predictive models against cancer: an IMODI integrative approach. , 2016, , .		0
49	Abstract A23: Characterization of novel molecular vulnerabilities provoking replicative and energetic stresses in pancreatic cancer cells. , 2016, , .		0
50	Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia. Blood, 2016, 128, 1636-1636.	1.4	2
51	Antileukemic Activity of 2-Deoxy-<scp>d</scp>-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. Molecular Cancer Therapeutics, 2015, 14, 2364-2373.	4.1	52
52	A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer Journal, 2015, 5, e297-e297.	6.2	68
53	Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation. Cancer & Metabolism, 2015, 3, 8.	5.0	36
54	The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations. Blood, 2015, 126, 2542-2542.	1.4	4

#	Article	IF	Citations
55	Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. PLoS ONE, 2015, 10, e0123721.	2.5	151
56	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.	1.8	20
57	Abstract 4068:In vivoanalysis of the residual disease uncovers early and late response of cytarabine-resistant cells in human acute myeloid leukemia. , 2015, , .		0
58	Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML. Blood, 2015, 126, 90-90.	1.4	0
59	In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells. Blood, 2015, 126, 4269-4269.	1.4	2
60	The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs. Cell Reports, 2014, 7, 1815-1823.	6.4	86
61	A Novel Path for ATRA Differentiation Therapy in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations. Blood, 2014, 124, 3727-3727.	1.4	1
62	Abstract 1336: Bortezomib induces the degradation of FLT3-ITD tyrosine kinase in acute myeloid leukemia through an autophagy-dependent mechanism. , 2014, , .		0
63	Abstract 2678: All-trans-retinoic acid as a new therapeutic approach to target isocitrate dehydrogenase mutations in acute myeloid leukemia. , 2014, , .		0
64	Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia. Blood, 2014, 124, 3767-3767.	1.4	0
65	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	1.4	53
66	Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia, 2013, 27, 2129-2138.	7.2	108
67	The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia, 2013, 27, 325-335.	7.2	17
68	Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. Blood, 2013, 122, 1651-1651.	1.4	2
69	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011, 96, 1792-1798.	3.5	164
70	Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion, 2011, 11, 342-350.	3.4	44
71	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2RÎ³c-deficient mice. Journal of Clinical Investigation, 2011, 121, 384-395.	8.2	336
72	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget, 2011, 2, 850-861.	1.8	29

#	Article	IF	Citations
73	Metabolic Capability to Induce the Pasteur Effect Mediates Sensitivity of Human Leukemic Cells to Metformin. Blood, 2011, 118, 2601-2601.	1.4	0
74	Ara-C Treatment of Acute Myeloid Leukemia Does Not Lead to Prolonged Enrichment of Stem Cells or a Cell Cycle Arrest. Blood, 2010, 116, 2178-2178.	1.4	0
75	Anti-Leukemic Activity of PIK-75, a PI3-Kinase p110Î± Selective Inhibitor, In Acute Myeloid Leukemia. Blood, 2010, 116, 659-659.	1.4	0
76	A robust xenotransplantation model for acute myeloid leukemia. Leukemia, 2009, 23, 2109-2117.	7.2	113
77	Acute Myeloid Leukemia Stem Cells Cells Are Rare and Heterogeneous in Human Acute Myeloid Leukemia.. Blood, 2009, 114, 390-390.	1.4	3
78	Combined Mass Mapping and Biochemical Characterization of Grape Î²-Glycosidase-enriched Extract. Protein Journal, 2008, 27, 258-266.	1.6	2
79	A Robust Xenotransplantation Model for Acute Myeloid Leukemia. Blood, 2008, 112, 2939-2939.	1.4	0
80	Analysis of the vacuolar luminal proteome of Saccharomyces cerevisiae. FEBS Journal, 2007, 274, 4287-4305.	4.7	33
81	Metabolomic, proteomic andÂbiophysical analyses ofÂArabidopsisÂthaliana cells exposed toÂaÂcaesium stress. Influence ofÂpotassium supply. Biochimie, 2006, 88, 1533-1547.	2.6	79
82	The early responses ofArabidopsis thaliana cells to cadmium exposure explored by protein and metabolite profiling analyses. Proteomics, 2006, 6, 2180-2198.	2.2	348
83	Dynamics ofArabidopsis thaliana soluble proteome in response to different nutrient culture conditions. Electrophoresis, 2006, 27, 495-507.	2.4	24
84	Grape berry biochemistry revisited upon proteomic analysis of the mesocarp. Proteomics, 2004, 4, 201-215.	2.2	136
85	Plant and microbial glycoside hydrolases: Volatile release from glycosidic aroma precursors. Food Chemistry, 2004, 87, 509-521.	8.2	222
86	The protective function of the xanthophyll cycle in photosynthesis. FEBS Letters, 1994, 353, 147-150.	2.8	67
87	IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0